GLI1: A Therapeutic Target for Cancer

por Avery, Justin T., Zhang, Ruowen, Boohaker, Rebecca J.
Publicado 2021

A radiosensitivity MiRNA signature validated by the TCGA database for head and neck squamous cell carcinomas

por Liu, Ning, Boohaker, Rebecca J., Jiang, Chunling, Boohaker, James R., Xu, Bo
Publicado 2015

High anti-tumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model

por Griffin, Patricia, Hill, Wendy A., Rossi, Fabio, Boohaker, Rebecca, Stinson, Karr, Sherman, Igor
Publicado 2023

DNA mismatch repair protein Mlh1 is required for tetravalent chromium intermediate-induced DNA damage

por Wakeman, Timothy P., Yang, Aimin, Dalal, Naresh S., Boohaker, Rebecca J., Zeng, Qinghua, Ding, Qiang, Xu, Bo
Publicado 2017

GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAF(V600E) Colorectal Cancer

por Zhang, Ruowen, Ma, Jinlu, Avery, Justin T., Sambandam, Vijaya, Nguyen, Theresa H., Xu, Bo, Suto, Mark J., Boohaker, Rebecca J.
Publicado 2020

A disease-relevant mutation of SPOP highlights functional significance of ATM-mediated DNA damage response

por Xiao, Mingming, Fried, Joshua S., Ma, Jinlu, Su, Yang, Boohaker, Rebecca J., Zeng, Qinghua, Mo, Yaqi, Meng, Fanbiao, Xiang, Rong, Xu, Bo
Publicado 2021

Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma

por Cox, Amanda, Nierenberg, Daniel, Camargo, Oscar, Lee, Eunkyung, Khaled, Amr S., Mazar, Joseph, Boohaker, Rebecca J., Westmoreland, Tamarah J., Khaled, Annette R.
Publicado 2022

Dual-functional significance of ATM-mediated phosphorylation of spindle assembly checkpoint component Bub3 in mitosis and the DNA damage response

por Xiao, Mingming, Zhang, Siyue, Liu, Zhuang, Mo, Yaqi, Wang, Han, Zhao, Xu, Yang, Xue, Boohaker, Rebecca J., Chen, Yang, Han, Yamei, Liu, Hong, Xu, Bo
Publicado 2022

A MicroRNA Expression Signature In Taxane-anthracycline-based Neoadjuvant Chemotherapy Response

por Zheng, Yi, Li, Shuai, Boohaker, Rebecca J, Liu, Xinli, Zhu, Yufen, Zhai, Lili, Li, Huilan, Gu, Feng, Fan, Yu, Lang, Ronggang, Liu, Fangfang, Qian, Xiaolong, Xu, Bo, Fu, Li
Publicado 2015

Integrative Analyses Reveal the Anticancer Mechanisms and Sensitivity Markers of the Next-Generation Hypomethylating Agent NTX-301

por Lim, Byungho, Yoo, Dabin, Chun, Younghwa, Go, Areum, Kim, Ji Yeon, Lee, Ha Young, Boohaker, Rebecca J., Cho, Kyung-Jin, Ahn, Sunjoo, Lee, Jin Soo, Jung, DooYoung, Choi, Gildon
Publicado 2023

The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia

por Lim, Byungho, Yoo, Dabin, Chun, Younghwa, Go, Areum, Cho, Kyung-Jin, Choi, Daeun, Jung, Myoung Eun, Lee, Ha Young, Boohaker, Rebecca J., Lee, Jin Soo, Jung, DooYoung, Choi, Gildon
Publicado 2022